On June 20, 2019 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") reported its presence at the upcoming SNMMI or Society of Nuclear Medicine and Molecular Imaging 2019 Annual Meeting being held June 22nd – 25th in Anaheim, California (Press release, Actinium Pharmaceuticals, JUN 20, 2019, View Source [SID1234537190]). In total, two oral and two poster presentations highlighting Actinium’s programs will be presented at SNMMI. In addition, Actinium’s Chief Scientific Officer, Dr. Dale Ludwig, will participate in a panel at the Ac-225 User Group at SNMMI to discuss the use of the radioisotope Ac-225 or Actinium-225 produced by the of U.S. Department of Energy via a high-energy linear accelerator. Actinium has demonstrated feasibility in generating ARC’s or Antibody Radiation-Conjugates with linear accelerator produced Ac-225.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Actinium’s lead program, Iomab-B, which is being studied in the pivotal Phase 3 SIERRA trial, will be highlighted in two oral presentations at SNMMI. The two oral presentations will focus on the dosimetry of Iomab-B, which is used to tailor personalized doses for each patient in the SIERRA trial. Dosimetry allows for high levels of the isotope I-131 or Iodine-131 to be delivered in a patient specific doses, which has facilitated engraftment in all patients that received Iomab-B and a BMT or Bone Marrow Transplant in the first 25% of patients enrolled in the SIERRA trial. In addition, findings from a multi-center team suggest that dosimetry imaging optimization may be possible with Iomab-B, which could result in benefits for patients and treatment centers including a reduction in the number and time required for imaging.
The two poster presentations will highlight Actinium’s AWE or Antibody Warhead Enabling Technology Platform that Actinium utilizes to empower its pipeline of ARC’s. A poster will highlight the ARC comprised of the anti-CD38 antibody daratumumab, which is marketed as Darzalex by Johnson & Johnson for patients with Multiple Myeloma, labeled with the radioisotope actinium-225. In addition, a poster presentation will highlight Actinium’s expansion of its Iomab-ACT for lymphodepletion prior to CAR-T and other adoptive cell therapies. Actinium’s Iomab-ACT program, which is a lower dose of Iomab-B, is intended to eliminate chemotherapy based conditioning agents such as Flu/Cy or Fludarabine and Cyclophosphamide. The poster will highlight the use of the radioisotope Lu-177 or Lutetium-177 with an anti-CD45 antibody, which has the potential to expand the radioisotope warheads that Actinium can utilize to achieve lymphodepletion prior to CAR-T and other adoptive cell therapies with its ARC’s. The poster at SNMMI will be the first time that Actinium is presenting data on the use of Lu-177 with a CD45 targeting moiety.
Details of the SNMMI presentations are as follows:
Oral Presentations:
Session Title: SS51: Other Solid Tumors/ Hematologic Malignancies (Clinical) I
Date & Time: Tuesday, June 25th, 8:00 AM – 9:30 AM
Location: Room 202AB, Anaheim Convention Center
Publication 433
Presenter: Neeta Pandit-Taskar MD, Memorial Sloan Kettering Cancer Center
Time: 9:10-9:20 AM
Title: Optimizing Dosimetry Imaging in High dose Radioimmunotherapy Using the Novel, AntiCD45 Reinduction and Targeted Conditioning Agent Iodine (131I) Apamistamab [IomabB] in Patients 55 Years or Older with Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA Phase III Trial)
Publication 434
Presenter: Neeta Pandit-Taskar MD, Memorial Sloan Kettering Cancer Center (on behalf of first author Landis Griffeth MD, Baylor University Medical Center)
Time: 9:20-9:30 AM
Title: Personalized Dosimetry using 131I-anti-CD45-Apamistamab (Iomab-B) Prior to High-dose Myeloablative Radioimmunotherapy for Hematopoietic Stem Cell Transplant (HCT) in Active, Relapsed, or Refractory Acute Myelogenous Leukemia: Novel Re-induction and Targeted Conditioning Feasibility and Engraftment Results from the SIERRA Trial
Poster Presentations:
Session Title: MTA I: Oncology, Basic and Translational (Basic Science) Posters
Date & Time: Monday, June 24th, 3:00 PM – 4:30 PM
Location: Poster Hall, Exhibit Hall, Anaheim Convention Center
Poster 1410
Presenter: Dr. Ekaterina Dadachova, University of Saskatchewan
225Ac-CD38 antibody targeting is effective and well tolerated in experimental models of lymphoma and multiple myeloma
Poster 1420
Presenter: Dr. Dale Ludwig, Actinium Pharmaceuticals, Inc.
Modeling targeted lymphodepletion with 177Lu-radiolabeled CD45 antibody as a preparative regimen prior to adoptive cell therapy
Ac-225 User Group at SNMMI
Date and Time: Sunday, June 23rd 4:00 – 5:00 PM PT
Location: Platinum Ballroom Salon 3 in Anaheim Marriott